8月20日周三盘中，歌礼制药-B（01672.HK）股价大跌5.03%，引发市场关注。本次股价下跌主要受到公司最新配股计划以及较高的沽空压力的影响。
据悉，歌礼制药-B宣布以先旧后新方式进行配股，配股价格定为每股16.45港元。公司此次配股所得款项总额约为4.74亿港元，净额约为4.68亿港元。歌礼制药-B表示，约90%的募集资金将用于其皮下注射多肽及口服多肽候选药物的肥胖症临床试验研发，剩余约10%将用作营运资金及其他一般公司用途。
值得注意的是，歌礼制药-B的配股价格低于当前市场交易价格，这可能引发了投资者对股票价值的担忧，从而导致股价下跌。此外，根据市场数据，歌礼制药-B的沽空比率达到29.51%，偏离值排名市场第五，显示出较高的做空压力，这也可能是加剧股价下跌的因素之一。在这种情况下，投资者对该股票的态度趋于谨慎，进一步加大了股价的下行压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.